591. Kuoppamaki M, Palvimaki EP, Hietala J, Syvalahti E:
Differential regulation of rat 5-HT
2A
and 5-HT
2C
receptors after chronic treatment with clozapine, chlorpromazine and three putative atypical antipsychotic drugs.
Neuropsychopharmacology
1995,
13
(2):139-150.
592. Gobbi G, Janiri L:
Clozapine blocks dopamine, 5-HT
2
and 5-HT
3
responses in the medial prefrontal cortex: an
in vivo
microiontophoretic study.
Eur Neuropsychopharmacol
1999,
10
(1):43-49.
593. Hermann B, Wetzel CH, Pestel E, Zieglgansberger W, Holsboer F, Rupprecht R:
Functional antagonistic properties of clozapine at the 5-HT
3
receptor.
Biochem Biophys Res Commun
1996,
225
(3):957-960.
594. Theisen FM, Haberhausen M, Firnges MA, Gregory P, Reinders JH, Remschmidt H, Hebebrand J, Antel J:
No evidence for binding of clozapine, olanzapine and/or haloperidol to selected receptors involved in body weight regulation.
Pharmacogenomics J
2007,
7
(4):275-281.
595. Frederick JA, Meador-Woodruff JH:
Effects of clozapine and haloperidol on 5-HT
6
receptor mRNA levels in rat brain.
Schizophr Res
1999,
38
(1):7-12.
596. Tauscher J, Hussain T, Agid O, Verhoeff NP, Wilson AA, Houle S, Remington G, Zipursky RB, Kapur S:
Equivalent occupancy of dopamine D1 and D2 receptors with clozapine: differentiation from other atypical antipsychotics.
Am J Psychiatry
2004,
161
(9):1620-1625.
597. Burstein ES, Ma J, Wong S, Gao Y, Pham E, Knapp AE, Nash NR, Olsson R, Davis RE, Hacksell U,
et al.
:
Intrinsic efficacy of antipsychotics at human D2, D3, and D4 dopamine receptors: identification of the clozapine metabolite N-desmethylclozapine as a D2/D3 partial agonist.
J Pharmacol Exp Ther
2005,
315
(3):1278-1287.
598. Cussac D, Pasteau V, Millan MJ:
Characterisation of G
s
activation by dopamine D1 receptors using an antibody capture assay: antagonist properties of clozapine.
Eur J Pharmacol
2004,
485
(1-3):111-117.
599. Lanig H, Utz W, Gmeiner P:
Comparative molecular field analysis of dopamine D4 receptor antagonists including 3-[4-(4-chlorophenyl)piperazin-1-ylmethyl]pyrazolo[1,5-a]pyridine (FAUC 113), 3-[4-(4-chlorophenyl)piperazin-1-ylmethyl]-1H-pyrrolo-[2,3-b]pyridine (L-745,870), and clozapine.
J Med Chem
2001,
44
(8):1151-1157.
600. Pao SK, Dickerson JW:
Effect of a low protein diet and isoenergetic amounts of a high protein diet in the weanling rat on the free amino acids of the brain.
Nutr Metab
1975,
18
(4):204-216.
601. Fujita Y, Yamamoto T, Rikimaru T, Inoue G:
Effect of low protein diets on free amino acids in plasma of young men: effect of wheat gluten diet.
J Nutr Sci Vitaminol (Tokyo)
1979,
25
(5):427-439.
602. Suzic S, Radunovic L, Jankovic V, Segovic R:
Effects of protein-free diet in amino acid homeostasis of rat blood plasma and gut contents.
FEBS Lett
1987,
216
(2):287-290.
603. Shim SS, Hammonds MD, Kee BS:
Potentiation of the NMDA receptor in the treatment of schizophrenia: focused on the glycine site.
Eur Arch Psychiatry Clin Neurosci
2008,
258
(1):16-27.
604. Sagvolden T, Johansen EB, Aase H, Russell VA:
A dynamic developmental theory of attention-deficit/hyperactivity disorder (ADHD) predominantly hyperactive/impulsive and combined subtypes.
Behav Brain Sci
2005,
28
(3):397-419; discussion 419-368.
605. Jackson ME, Homayoun H, Moghaddam B:
NMDA receptor hypofunction produces concomitant firing rate potentiation and burst activity reduction in the prefrontal cortex.
Proc Natl Acad Sci U S A
2004,
101
(22):8467-8472.
606. Volkow ND, Fowler JS, Wang GJ, Telang F, Logan J, Wong C, Ma J, Pradhan K, Benveniste H, Swanson JM:
Methylphenidate decreased the amount of glucose needed by the brain to perform a cognitive task.
PLoS ONE
2008,
3
(4):e2017.
607. Barton J:
Atomoxetine: a new pharmacotherapeutic approach in the management of attention deficit/hyperactivity disorder.
Arch Dis Child
2005,
90
(Suppl 1):i26-i29.
608. Brannan T, Martinez-Tica J, Yahr MD:
Effect of dietary protein on striatal dopamine formation following L-dopa administration: an
in vivo
study.
Neuropharmacology
1991,
30
(10):1125-1127.
609. Montgomery AJ, McTavish SF, Cowen PJ, Grasby PM:
Reduction of brain dopamine concentration with dietary tyrosine plus phenylalanine depletion: an [
11
C]raclopride PET study.
Am J Psychiatry
2003,
160
(10):1887-1889.
610. Tam SY, Elsworth JD, Bradberry CW, Roth RH:
Mesocortical dopamine neurons: high basal firing frequency predicts tyrosine dependence of dopamine synthesis.
J Neural Transm Gen Sect
1990,
81
(2):97-110.
611. Hayashi M, Bandoh T, Ushizawa D, Takada S, Hoshi K:
Effects of acute and short-term administration of tryptophan plus ethanol on noradrenaline and serotonin metabolites in the
locus coeruleus
.
Alcohol
2004,
34
(2-3):225-232.
612. Gibson CJ, Deikel SM, Young SN, Binik YM:
Behavioural and biochemical effects of tryptophan, tyrosine and phenylalanine in mice.
Psychopharmacology (Berl)
1982,
76
(2):118-121.
613. Denbow DM, Hobbs FC, Hulet RM, Graham PP, Potter LM:
Supplemental dietary L-tryptophan effects on growth, meat quality, and brain catecholamine and indoleamine concentrations in turkeys.
Br Poult Sci
1993,
34
(4):715-724.
614. Lehnert H, Reinstein DK, Strowbridge BW, Wurtman RJ:
Neurochemical and behavioral consequences of acute, uncontrollable stress: effects of dietary tyrosine.
Brain Res
1984,
303
(2):215-223.
615. McTavish SF, McPherson MH, Harmer CJ, Clark L, Sharp T, Goodwin GM, Cowen PJ:
Antidopaminergic effects of dietary tyrosine depletion in healthy subjects and patients with manic illness.
Br J Psychiatry
2001,
179
:356-360.
616. Reimherr FW, Wender PH, Wood DR, Ward M:
An open trial of L-tyrosine in the treatment of attention deficit disorder, residual type.
Am J Psychiatry
1987,
144
(8):1071-1073.
617. Wood DR, Reimherr FW, Wender PH:
Treatment of attention deficit disorder with DL-phenylalanine.
Psychiatry Res
1985,
16
(1):21-26.
618. Johnston JL, Balachandran AV:
Effects of dietary protein, energy and tyrosine on central and peripheral norepinephrine turnover in mice.
J Nutr
1987,
117
(12):2046-2053.
619. Peters JC, Harper AE:
Adaptation of rats to diets containing different levels of protein: effects on food intake, plasma and brain amino acid concentrations and brain neurotransmitter metabolism.
J Nutr
1985,
115
(3):382-398.
620. Juhila J, Honkanen A, Sallinen J, Haapalinna A, Korpi ER, Scheinin M:
alpha
2A
-Adrenoceptors regulate d-amphetamine-induced hyperactivity and behavioural sensitization in mice.
Eur J Pharmacol
2005,
517
(1-2):74-83.
621. Wooters TE, Dwoskin LP, Bardo MT:
Age and sex differences in the locomotor effect of repeated methylphenidate in rats classified as high or low novelty responders.
Psychopharmacology (Berl)
2006,
188
(1):18-27.
622. Vollmer TR, Borrero JC, Lalli JS, Daniel D:
Evaluating self-control and impulsivity in children with severe behavior disorders.
J Appl Behav Anal
1999,
32
(4):451-466.
623. Aoki N, Suzuki R, Izawa E, Csillag A, Matsushima T:
Localized lesions of ventral striatum, but not arcopallium, enhanced impulsiveness in choices based on anticipated spatial proximity of food rewards in domestic chicks.
Behav Brain Res
2006,
168
(1):1-12.
624. Grace AA:
The tonic/phasic model of dopamine system regulation: its relevance for understanding how stimulant abuse can alter basal ganglia function.
Drug Alcohol Depend
1995,
37
(2):111-129.
625. Volkow ND, Wang GJ, Fowler JS, Ding YS:
Imaging the effects of methylphenidate on brain dopamine: new model on its therapeutic actions for attention-deficit/hyperactivity disorder.
Biol Psychiatry
2005,
57
(11):1410-1415.
626. Srinivasarao P, Narayanareddy K, Vajreswari A, Rupalatha M, Prakash PS, Rao P:
Influence of dietary fat on the activities of subcellular membrane-bound enzymes from different regions of rat brain.
Neurochem Int
1997,
31
(6):789-794.
627. Nathan PJ, Baker A, Carr E, Earle J, Jones M, Nieciecki M, Hutchison C, Stough C:
Cholinergic modulation of cognitive function in healthy subjects: acute effects of donepezil, a cholinesterase inhibitor.
Hum Psychopharmacol
2001,
16
(6):481-483.
628. Knudsen EI:
Fundamental components of attention.
Annu Rev Neurosci
2007,
30
:57-78.
629. Murphy P, Burnham WM:
The ketogenic diet causes a reversible decrease in activity level in Long-Evans rats.
Exp Neurol
2006,
201
(1):84-89.
630. Murphy P, Likhodii SS, Hatamian M, McIntyre Burnham W:
Effect of the ketogenic diet on the activity level of Wistar rats.
Pediatr Res
2005,
57
(3):353-357.
631. Senn S:
The AB/BA crossover: past, present and future?
Stat Methods Med Res
1994,
3
(4):303-324.
632. Senn S:
Cross-over trials in Statistics in Medicine: the first ‘25’ years.
Stat Med
2006,
25
(20):3430-3442.
633. Power Analysis and Sample Size software, NCSS
http://www.ncss.com/pass.html
634. Jacobson NS, Truax P:
Clinical significance: a statistical approach to defining meaningful change in psychotherapy research.
J Consult Clin Psychol
1991,
59
(1):12-19.
635. Test of Variables of Attention
http://www.tovatest.com/
636. Cornblatt BA, Risch NJ, Faris G, Friedman D, Erlenmeyer-Kimling L:
The Continuous Performance Test, identical pairs version (CPT-IP): I. New findings about sustained attention in normal families.
Psychiatry Res
1988,
26
(2):223-238.
637. Conners’ Continuous Performance Test II
http://mhs.com/product.aspx?gr=edu&prod=cptii5
638. The T.O.V.A. Professional Manual
http://www.tovatest.com/research-and-education/
639. Frosini M, Sesti C, Palmi M, Valoti M, Fusi F, Mantovani P, Bianchi L, Della Corte L, Sgaragli G:
The possible role of taurine and GABA as endogenous cryogens in the rabbit: changes in CSF levels in heat-stress.
Adv Exp Med Biol
2000,
483
:335-344.
640. Ghosh S, Poddar MK:
Higher environmental temperature: effect of multiple exposures on long-term diazepam-induced changes in brain regional GABA.
Methods Find Exp Clin Pharmacol
1995,
17
(3):175-184.
641. Dey S, Dey PK, Sharma HS:
Regional metabolism of 5-hydroxytryptamine in brain under acute and chronic heat stress.
Indian J Physiol Pharmacol
1993,
37
(1):8-12.
642. Sharma HS, Dey PK:
Influence of long-term acute heat exposure on regional blood-brain barrier permeability, cerebral blood flow and 5-HT level in conscious normotensive young rats.
Brain Res
1987,
424
(1):153-162.